Regulatory Landscape and Clinical Implication of MBD3 in Human Malignant Glioma [low-grade glioma and glioblastoma screening]. Homo sapiens

A comprehensive study is conducted to inspect the role and function of methyl-CpG-binding domain protein 3 (MBD3) in human malignant glioma, as well as to test its potential as a novel prognostic biomarker. Using whole-genome microarray for transcriptome, the MBD3-mediated epigenetic regulation in glioma was profiled. Overall design: A negative correlation between the glioma WHO grade and the MBD3 protein level was first revealed in our collected patient biopsies. Therefore, the differentiated expressed genes between low-grade glioma (WHO grade II) and glioblastoma (GBM, WHO grade IV) were screened. Four patients with characterized glioma grade were enrolled in each group.

本研究开展了一项综合分析，旨在探究甲基-CpG结合域蛋白3（methyl-CpG-binding domain protein 3, MBD3）在人类恶性胶质瘤中的作用与功能，并验证其作为新型预后生物标志物的潜力。本研究采用全基因组转录组微阵列技术，对胶质瘤中MBD3介导的表观遗传调控进行了谱分析。整体实验设计：首先在我们收集的患者活检样本中，发现胶质瘤WHO分级与MBD3蛋白水平呈负相关；据此筛选出低级别胶质瘤（WHO Ⅱ级）与胶质母细胞瘤（glioblastoma, GBM，WHO Ⅳ级）之间的差异表达基因。每组纳入4名经明确胶质瘤分级的患者。